drugset / Trial / NCT00657553

Preemptive Strike With Bortezomib in Multiple Myeloma Patients

NCT00657553

Phase 3 Terminated 10 enrolled University of Arkansas
RandomizedSingle-groupOpen-labelTreatment

Summary

To evaluate whether using the drug bortezomib at the start of remission will prevent relapse for a longer period of time.

Timeline

Start
2008-02
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bortezomib Small molecule 1 mg/m2 Intravenous

Indications